Founding Organizations:

Join Dr. Roytman, hepatologist at UCSF Fresno, as she opens a full-day educational symposium on steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)—formerly known as NAFLD and NASH. This CME-accredited program, supported by Madrigal Pharmaceuticals and organized by the Global NASH Council and CLDF, delivers expert guidance on recognizing, staging, and managing this fast-growing global health crisis.

Dr. Roytman walks through the epidemiological trends of MASLD and emphasizes the alarming rates in patients with type 2 diabetes, especially in North and Latin America. She outlines the clinical significance of F2 fibrosis, which carries a 2.5x higher liver-related mortality, and details why identifying early-stage fibrosis is critical.

This session highlights non-invasive testing (NIT) strategies—including FIB-4, FibroScan (VCTE), FAST score, ELF test, and MRE—to assess liver fibrosis and steatosis without the need for biopsy. Practical insights are provided on when to refer to hepatology, when to monitor with NITs, and how to interpret test thresholds to detect cirrhosis.

Learn how lifestyle modifications, including 10% total body weight loss, Mediterranean diet, intermittent fasting, and aerobic and resistance training, contribute to fibrosis regression and liver health. Dr. Roytman discusses patient communication strategies and adapting dietary plans across diverse populations.

The centerpiece of this talk is an in-depth review of resmetirom (Rezdiffra)—the first FDA-approved treatment for MASH with F2 or F3 fibrosis. Dr. Roytman explains the mechanism of action as a THR-β agonist, the importance of combining it with lifestyle changes, and how to monitor patients over 12 months using ALT levels and liver stiffness measurements. She also outlines when to initiate or discontinue therapy and patient populations most likely to benefit (e.g., post-bariatric surgery with residual fibrosis).